Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MPL | P40238 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24175939 | 0.88 | HTT (0.43) | HTTSMN1; SMN2HSD17B10ALDH1A1LMNA | |
| SCHEMBL24785026 | 0.88 | HTT (0.50) | HTTSMN1; SMN2HSD17B10ALDH1A1LMNA | |
| SCHEMBL26301854 | 0.87 | ALDH1A1 (0.41) | HTTSMN1; SMN2HSD17B10ALDH1A1LMNA | |
| SCHEMBL27051943 | 0.85 | HTT (0.54) | HTTSMN1; SMN2HSD17B10ALDH1A1LMNA | |
| SCHEMBL27051929 | 0.84 | ALDH1A1 (0.39) | HTTSMN1; SMN2HSD17B10ALDH1A1LMNA | |
| SCHEMBL27051962 | 0.81 | SMN1; SMN2 (0.49) | HTTSMN1; SMN2HSD17B10ALDH1A1LMNA | |
| SCHEMBL27051926 | 0.81 | CYP3A4 (0.40) | HTTSMN1; SMN2HSD17B10ALDH1A1LMNA | |
| SCHEMBL27051934 | 0.81 | HSD17B10 (0.44) | HTTSMN1; SMN2HSD17B10ALDH1A1LMNA | |
| SCHEMBL27051932 | 0.80 | KHK (0.38) | HTTSMN1; SMN2ALDH1A1LMNANPC1 | |
| SCHEMBL27051800 | 0.79 | HTT (0.46) | HTTSMN1; SMN2HSD17B10ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | HTT 1987/4885SMN1; SMN2 3857/4885HSD17B10 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.